Multiple Myeloma

Data from the ongoing phase 1/2 MajesTEC-1 study suggested that treatment with the BCMA x CD3 bispecific antibody teclistamab induced deep and durable responses in heavily pretreated patients with RRMM, with a manageable safety profile.

Updated results of the KarMMa trial showed that ide-cel CAR T-cell therapy resulted in durable and deep responses in heavily pretreated, triple-class–exposed patients with RRMM, supporting an overall favorable clinical benefit–risk profile.

In 2022, the COVID-19 pandemic continues to impact the practice of medicine and the dissemination of treatment advances presented in scientific forums.

Updated results of the ICARIA-MM study demonstrated that addition of isatuximab to pomalidomide/low-dose dexamethasone led to significant improvements in efficacy outcomes compared with pomalidomide/low-dose dexamethasone alone in patients with RRMM.

Preliminary data suggest that patients with both MM and WM show impaired serologic responses following COVID-19 vaccines, with more severe impairment of COVID-19 S-protein antibody responses observed in the Waldenström macroglobulinemia cohort, and mRNA-1273 eliciting higher responses than other vaccines.

Results of a multicohort, phase 1/2 study indicated that the novel cereblon E3 ligase modulator iberdomide plus dexamethasone and daratumumab, bortezomib, or carfilzomib was associated with a tolerable safety profile and promising antitumor activity in patients with heavily pretreated RRMM.

Results of the CARDAMON trial indicate that, although carfilzomib maintenance was feasible and yielded higher MRD negativity rates at 6 months with ASCT than with consolidation, it was associated with a higher incidence of grade ≥3 adverse events and discontinuations after ASCT.

Interim analysis results of the phase 3 MAIA trial demonstrated that frontline daratumumab plus lenalidomide/dexamethasone provided OS benefit compared with lenalidomide/dexamethasone in patients with NDMM ineligible for stem-cell transplantation.

In the CARTITUDE-2 cohort A that included patients with MM who had received 1 to 3 previous lines of therapy and were lenalidomide-refractory, a single infusion of cilta-cel CAR T-cell therapy produced early and deep responses, with a manageable safety profile.

Initial primary analysis results of the ongoing phase 3 GMMG-HD7 trial demonstrated that the addition of isa­tuximab to the standard-of-care RVd regimen was associated with superior MRD negativity rates after induction, and the regimen was not accompanied by emergence of new safety signals or early discontinuation.